Cannabis Compounds: The New Liver Fat Busters?

A man carefully harvesting cannabis plants in a greenhouse

Two non-intoxicating cannabis compounds have slashed liver fat and remodeled metabolism in laboratory models of the world’s most common chronic liver disease, but the path from petri dish to prescription bottle is littered with cautionary tales.

Story Snapshot

CBD and CBG reduced liver fat and improved glucose control in preclinical models of metabolic dysfunction-associated steatotic liver disease (MASLD) through a novel dual mechanism involving energy buffering and cellular cleanup.
CBG outperformed CBD in several key metrics, including body fat reduction, insulin sensitivity, and cholesterol lowering, positioning the lesser-known cannabinoid as a potential therapeutic lead.
The Hebrew University study identified phosphocreatine energy reserves and lysosomal restoration as specific pathways, offering mechanistic depth beyond generic “anti-inflammatory” explanations.
Findings remain strictly experimental with no human clinical trials yet underway, despite MASLD affecting millions globally with few approved drug treatments.

The Dual Mechanism Behind the Metabolic Overhaul

Researchers at Hebrew University of Jerusalem fed animal models high-fat diets to induce fatty liver disease, then administered CBD and CBG. The cannabinoids increased hepatic phosphocreatine, an emergency energy reserve that buffers stressed liver cells when ATP runs low. Simultaneously, they reactivated lysosomal cathepsins, enzymes responsible for breaking down and clearing harmful lipids and cellular waste. This dual action constitutes what lead investigator Prof. Joseph Tam calls metabolic remodeling: liver cells gained both the energy to function under metabolic stress and the machinery to clean house. The result was measurable drops in liver fat, triglycerides, and ceramides, lipids strongly linked to insulin resistance and inflammation.

CBG emerged as the stronger performer in head-to-head comparisons. Beyond reducing liver steatosis, CBG drove down total body fat mass more effectively than CBD, sharpened insulin sensitivity, and delivered more robust reductions in total and LDL cholesterol. These cardiometabolic benefits matter because MASLD rarely travels alone; it clusters with obesity, type 2 diabetes, and cardiovascular risk factors. A therapy addressing multiple facets of metabolic syndrome holds theoretical appeal, but CBG carries a thinner evidence base in humans than CBD, which already has FDA approval for certain epilepsies and a substantial safety dataset. The comparative edge in animal models does not automatically translate to superior outcomes in people, and the dose-response curves, drug interactions, and long-term safety profiles for CBG in metabolic disease remain largely uncharted territory.

Why This Mechanism Matters in a Crowded Field

MASLD, formerly called nonalcoholic fatty liver disease, now ranks as the most prevalent chronic liver condition worldwide, riding the coattails of the obesity and diabetes epidemics. The disease spectrum ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Despite this burden, the drug pipeline has delivered few approved therapies; lifestyle modification remains the clinical cornerstone, yet adherence is notoriously poor. Investigational NASH and MASH drugs have stumbled in late-stage trials, victims of modest efficacy, side effects, or failure to hit composite endpoints that satisfy regulators. The phosphocreatine and lysosomal pathways spotlighted by Tam’s group represent a mechanistic departure from earlier anti-inflammatory or anti-fibrotic strategies, potentially opening new avenues when traditional targets have disappointed.

The endocannabinoid system itself has long fascinated liver researchers. CB1 receptor activation promotes fat accumulation and metabolic dysfunction, while blocking CB1 improved outcomes in preclinical models and drove the development of the anti-obesity drug rimonabant. Rimonabant’s withdrawal after psychiatric adverse events chilled enthusiasm for direct CB1 antagonism, shifting attention toward non-intoxicating cannabinoids that modulate the system more subtly. CBD and CBG act through multiple pathways beyond classic cannabinoid receptors, influencing TRPV channels, PPARγ, and other targets. The current study adds lysosomal function and energy metabolism to that list, suggesting cannabinoids might bypass the pitfalls of strong receptor blockade while still delivering metabolic benefits. Whether that theoretical advantage survives scrutiny in controlled human trials is the billion-dollar question.

The Translational Gap and Regulatory Reality

Preclinical success in animal models is necessary but far from sufficient proof. Rodent metabolism differs significantly from human metabolism; dose equivalents are not straightforward, and animal models of MASLD imperfectly recapitulate the slow, multifactorial progression seen in patients. High-dose CBD in humans can elevate liver enzymes and interact with cytochrome P450 pathways, raising concerns about drug-drug interactions in MASLD populations that often take statins, antidiabetic agents, and antihypertensives. A large observational study found no major hepatic dysfunction signal in long-term CBD users compared with the general population, but mild enzyme elevations occurred, underscoring the need for careful monitoring. CBG’s human safety profile is even less characterized, with sparse published data on dosing, pharmacokinetics, or potential toxicities at therapeutic levels.

Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds

CBD and CBG may help the liver burn fat, restore metabolism, and fight fatty liver disease.#Cannabis https://t.co/fP0itkGZfo

— Cannabis Seed Bank of ME • R&D (@SeedBankME) March 6, 2026

Regulatory agencies demand rigorous phase I, II, and III trials demonstrating safety, efficacy, and quality before any cannabinoid-based therapy for MASLD reaches the market. That pipeline takes years and tens of millions of dollars, a timeline and investment that clash with the cannabis industry’s eagerness to capitalize on headlines. The risk is predictable: supplement and wellness companies will invoke this research in marketing materials, making implied or outright disease claims for over-the-counter CBD and CBG products that lack pharmaceutical-grade standardization, third-party testing, or clinical validation. Regulators have historically cracked down on such claims, but enforcement lags behind the flood of products. Consumers with fatty liver disease deserve treatments grounded in evidence, not extrapolations from mouse livers.

What Comes Next and Who Decides

The immediate scientific impact is clear: phosphocreatine buffering and lysosomal restoration are now on the map as cannabinoid-sensitive pathways in MASLD. Academic labs and biotech firms will test whether synthetic analogs, different cannabinoid ratios, or liver-targeted delivery systems can amplify the effect. Funders, whether public grant agencies or venture capital, will determine if early-phase human trials of pharmaceutical-grade CBD or CBG in MASLD move forward. Clinical guideline bodies and hepatology societies will weigh any eventual trial data against existing standards of care, a bar set high by the field’s previous disappointments. Patients, meanwhile, are left in a holding pattern: encouraged by the mechanistic novelty, yet reminded that laboratory promise and bedside reality occupy different worlds.

The broader implication extends beyond liver disease. Non-intoxicating cannabinoids gaining traction in metabolic and chronic disease research bolster the argument that cannabis-derived compounds have legitimate medical value outside pain management and seizure disorders. The Hebrew University study offers a compelling starting point, a scientifically grounded hypothesis worth testing in humans under controlled conditions. It does not offer a green light to treat fatty liver disease with shelf-stable gummies of uncertain provenance and potency. The next chapter will be written by clinical trialists, regulators, and patients willing to enroll in rigorous studies, not by marketers racing to print labels.